Efficacy and Safety of Endostar® Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas |
Zhang, Lu-Ping
(Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University)
Liao, Xing-Yun (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) Xu, Yan-Mei (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) Yan, Lv-Jun (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) Yan, Gui-Fang (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) Wang, Xin-Xin (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) Duan, Yu-Zhong (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) Sun, Jian-Guo (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) |
1 | Olsson AK, Johansson I, Akerud H, et al (2004). The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. Cancer Res, 64, 9012-17. DOI ScienceOn |
2 | Purohit S, Bhise R, Appachu S, et al (2011). Systemic therapy in soft tissue sarcomas: past, present and future. Indian J Surg Oncol, 2, 327-31. DOI ScienceOn |
3 | Reichardt P, Reichardt A, Pink D (2011). Molecular targeted therapy of gastrointestinal stromal tumors. Curr Cancer Drug Targets, 11, 688-97. DOI ScienceOn |
4 | Riedel RF (2012). Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches. Cancer, 118, 1474-85. DOI ScienceOn |
5 | Sasaki T, Janne PA (2011). New strategies for treatment of ALK-rearranged non-small cell lung cancers. Clin Cancer Res, 17, 7213-18. DOI |
6 | Shukla NK, Deo SV (2011). Soft tissue sarcoma-review of experience at a tertiary care cancer centre. Indian J Surg Oncol, 2, 309-12. DOI ScienceOn |
7 | Tsukagoshi S (2010). [Introductory remarks of the 9th International Conference of the Asian Clinical Oncology Society (ACOS) Congress--Talk to the World Wide from Asia]. Gan To Kagaku Ryoho, 37, 2021-23. |
8 | Vincenzi B, Napolitano A, D Onofrio L, et al (2011). Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside. Expert Opin Investig Drugs, 20, 1685-705. DOI ScienceOn |
9 | Wang J, Sun Y, Liu Y, et al (2005). [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]. Zhongguo Fei Ai Za Zhi, 8, 283-90. |
10 | Blay JY, Le CA, Cassier PA, et al (2012). Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes. Discov Med, 13, 357-67. |
11 | Brand TM, Iida M, Wheeler DL (2011). Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther, 11, 777-92. DOI |
12 | Cen L, Hsieh FC, Lin HJ, et al (2007). PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound. Br J Cancer, 97, 785-91. DOI ScienceOn |
13 | Cohen MH, Johnson JR, Chattopadhyay S, et al (2010). Approval summary: erlotinib maintenance therapy of advanced/ metastatic non-small cell lung cancer (NSCLC). Oncologist, 15, 1344-51. DOI ScienceOn |
14 | Cormier JN, Pollock RE (2004). Soft tissue sarcomas. CA Cancer J Clin, 54, 94-109. DOI ScienceOn |
15 | Folkman J (2002). Role of angiogenesis in tumor growth and metastasis. Semin Oncol, 29, 15-8. |
16 | Jiang LP, Zou C, Yuan X, et al (2009). N-terminal modification increases the stability of the recombinant human endostatin in vitro. Biotechnol Appl Biochem, 54, 113-20. DOI ScienceOn |
17 | Heudel P, Cassier P, Derbel O, et al (2012). Pazopanib for the treatment of soft-tissue sarcoma. Clin Pharmacol, 4, 65-70. |
18 | Italiano A, Mathoulin-Pelissier S, Cesne AL, et al (2011). Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer, 117, 1049-54. DOI ScienceOn |
19 | Jia Y, Liu M, Huang W, et al (2012). Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer. Pathol Oncol Res, 18, 315-23. DOI ScienceOn |
20 | Judson I (2010). Targeted therapies in soft tissue sarcomas. Ann Oncol, 21, vii277-80. DOI ScienceOn |
21 | Kaya M, Wada T, Nagoya S, et al (2007). Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin. J Orthop Sci, 12, 562-7. DOI |
22 | Ke QH, Zhou SQ, Huang M, et al (2012). Early efficacy of Endostar combined with chemoradiotherapy for advanced cervical cancers. Asian Pac J Cancer Prev, 13, 923-26. DOI ScienceOn |
23 | Li Y, Huang XE, Yan PW, et al (2010). Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Asian Pac J Cancer Prev, 11, 1119-23. |
![]() |